These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 17716129)

  • 21. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
    Mirtsching B; Cosgriff T; Harker G; Keaton M; Chidiac T; Min M
    Clin Breast Cancer; 2011 Apr; 11(2):121-8. PubMed ID: 21569998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.
    Vishnu P; Roy V
    Womens Health (Lond); 2010 Jul; 6(4):495-506. PubMed ID: 20597612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
    Chirgwin J; Chua SL
    Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain.
    Wiedenmann N; Valdecanas D; Hunter N; Hyde S; Buchholz TA; Milas L; Mason KA
    Clin Cancer Res; 2007 Mar; 13(6):1868-74. PubMed ID: 17363543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The winning formulation: the development of paclitaxel in pancreatic cancer.
    Ma WW; Hidalgo M
    Clin Cancer Res; 2013 Oct; 19(20):5572-9. PubMed ID: 23918602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
    Henderson IC; Bhatia V
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
    Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
    Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
    Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
    Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer.
    Moreno-Aspitia A; Perez EA
    Future Oncol; 2005 Dec; 1(6):755-62. PubMed ID: 16556053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.
    Ibrahim NK; Samuels B; Page R; Doval D; Patel KM; Rao SC; Nair MK; Bhar P; Desai N; Hortobagyi GN
    J Clin Oncol; 2005 Sep; 23(25):6019-26. PubMed ID: 16135470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery.
    Fu Q; Sun J; Zhang W; Sui X; Yan Z; He Z
    Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):262-72. PubMed ID: 19538176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
    Gradishar WJ; Tjulandin S; Davidson N; Shaw H; Desai N; Bhar P; Hawkins M; O'Shaughnessy J
    J Clin Oncol; 2005 Nov; 23(31):7794-803. PubMed ID: 16172456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on nanoparticle albumin-bound paclitaxel.
    Socinski M
    Clin Adv Hematol Oncol; 2006 Oct; 4(10):745-6. PubMed ID: 17099631
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
    Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors.
    Zhang L; Marrano P; Kumar S; Leadley M; Elias E; Thorner P; Baruchel S
    Clin Cancer Res; 2013 Nov; 19(21):5972-83. PubMed ID: 23989978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
    Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
    J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.
    Seidman AD; Conlin AK; Bach A; Moynahan ME; Lake D; Forero A; Wright GS; Hackney MH; Clawson A; Norton L; Hudis CA
    Clin Breast Cancer; 2013 Aug; 13(4):239-246.e1. PubMed ID: 23829890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparation and characterization of polymeric pH-sensitive STEALTH® nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel.
    Lundberg BB
    Int J Pharm; 2011 Apr; 408(1-2):208-12. PubMed ID: 21296135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficient delivery of therapeutic agents by using targeted albumin nanoparticles.
    Kouchakzadeh H; Safavi MS; Shojaosadati SA
    Adv Protein Chem Struct Biol; 2015; 98():121-43. PubMed ID: 25819278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.